Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05055752 · ClinicalTrials.gov registry record · Phase 1
Randomized, Crossover Bioequivalence Study of PL-ASA Versus Immediate Release Aspirin in Healthy Volunteers.
A Phase 1 study of Bioequivalence, sponsored by PLx Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT05055752 is a Phase 1 study of Bioequivalence that has completed, run by PLx Pharma. The registered enrollment target is 24 participants, below the 64-participant average among 3 other Bioequivalence trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05055752, a Phase 1 study of Bioequivalence, has completed, sponsored by PLx Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial is a randomized, actively-controlled, open-label, 2-way crossover bioequivalence study to determine PK parameters following treatment with test aspirin product (PL-ASA capsules) and reference aspirin product (IR-ASA tablets) administered at a single dose of 325 mg.
Conditions Studied
Interventions
- DRUG Pharmaceutical-lipid aspirin (PL-ASA)
Study Locations (1)
Kansas
- PRA-EDS - Lenexa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2020-05-07 |
| Est. Completion | 2020-10-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05055752
The ClinicalTrials.gov registry entry for NCT05055752 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 64-participant average among 3 other Bioequivalence trials with a reported enrollment target (62% lower). The listed sponsor is PLx Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bioequivalence appearing as the primary indexed condition, and to 1 intervention - of which Pharmaceutical-lipid aspirin (PL-ASA) is the first listed.
NCT05055752 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT05055752 about?
NCT05055752 is a clinical study titled "Randomized, Crossover Bioequivalence Study of PL-ASA Versus Immediate Release Aspirin in Healthy Volunteers.". This trial is a randomized, actively-controlled, open-label, 2-way crossover bioequivalence study to determine PK parameters following treatment with test aspirin product (PL-ASA capsules) and reference aspirin product (IR-ASA tablets) administered at a single dose of 325 mg.
What is the current status of trial NCT05055752?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2020-05-07. Estimated completion is 2020-10-01.
What conditions does trial NCT05055752 study?
This clinical trial studies the following conditions: Bioequivalence.
What interventions are being tested in trial NCT05055752?
The interventions under investigation include: Pharmaceutical-lipid aspirin (PL-ASA) (DRUG).
Who is sponsoring clinical trial NCT05055752?
This trial is sponsored by PLx Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05055752 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bioequivalence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of TEPEZZA Subcutaneous Administration in Healthy Adults
COMPLETED · Phase 1
-
Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Fasting Conditions
COMPLETED · Phase 1
-
A Phase 1 Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefilled Syringe Versus a Vial+Syringe Presentation in Healthy Adults
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.